Overall impact
C (53)

Commentary

Bayer is an average overall performer. With a 'C' rating of 53.1 for overall impact (47th percentile compared to all companies), Bayer ranks 503rd out of 585 industry peers, behind Grifols, Biogen, Ionis Pharmaceuticals and 499 others, and ahead of Jazz Pharmaceuticals, Citius Pharmaceuticals, Mereo BioPharma and 79 others. On top material causes for Bayer's industry (Pharmaceuticals & Biotech), Bayer performs well in Technology Innovation (95.3 score), Equal Pay and Opportunity (95.7), Access to Affordable Healthcare (95.9) and 2 other causes where it received an 'A' score and performs poorly in Child and Maternal Health (0.0 score), Racial Justice and Civil Rights (31.9), Reduced Use of tobacco (0.0) and 6 other causes where it received a 'D' or 'F' score.
Impact
Cause BAYZF
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
90,587
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Germany
Share classes
BAYZF
Mission
Science For A Better Life.
Description
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed management as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular, renal, and gynecological diseases; collaboration agreement with Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.
Material causes
Ethos considers the following causes material for Bayer, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.